Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03841565 |
|
Recruitment Status :
Withdrawn
(There are no patients enrolled on this study and all efforts are being discontinued.)
First Posted : February 15, 2019
Last Update Posted : June 15, 2022
|
Sponsor:
Academic and Community Cancer Research United
Collaborators:
Janssen Scientific Affairs, LLC
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Academic and Community Cancer Research United
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | February 9, 2022 |
| Actual Study Completion Date : | February 9, 2022 |